Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy

Journal of Medical Imaging and Radiation Oncology

Volumn 57, Issue 4, 2013, Pages 475-481

  Trinkaus, Mateya E ^a   Blum, Rob ^b   Rischin, Danny ^a   Callahan, Jason ^a   Bressel, Mathias ^a   Segard, Tatiana ^a   Roselt, Peter ^a   Eu, Peter ^a   Binns, David ^a   MacManus, Michael P ^a   Ball, David ^a   Hicks, Rodney J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Monash University and Bendigo Health Care Group   (Australia)

Author keywords

chemoradiation; FAZA; hypoxia; lung cancer; PET

Indexed keywords

CARBOPLATIN; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; GEFITINIB; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; FLUOROAZOMYCIN ARABINOSIDE; NITROIMIDAZOLE DERIVATIVE; DIAGNOSTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG METABOLISM; FAILURE FREE SURVIVAL; FEMALE; HUMAN; HYPOXEMIA; LUNG NON SMALL CELL CANCER; LUNG SCINTISCANNING; LUNG SURGERY; MALE; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL TIME; TREATMENT FAILURE; TUMOUR HYPOXIA; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CLINICAL TRIAL; DIAGNOSTIC USE; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY; FAZA; HYPOXIA; LUNG CANCER; LUNG TUMOR; METHODOLOGY; PET;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CHEMORADIOTHERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

CHEMORADIATION; FAZA; HYPOXIA; LUNG CANCER; PET;

EID: 84880706024     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/1754-9485.12086     Document Type: Article

References (23)

1. Tredan O, Galmarini CM, Patel K, Tannock IF,. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-1454.
2. Williamson SK, Crowley JJ, Lara PN, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005; 23: 9097-9104.
3. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000; 18: 1351-1359.
4. Yasuda H, Yamaya M, Nakayama K, et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2006; 24: 688-694.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. [Erratum appears in N Engl J Med. 2007 Jan 18;356(3):318]. N Engl J Med 2006; 355: 2542-2550.
6. Beck R, Roper B, Carlsen JM, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 2007; 48: 973-980.
7. Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006; 24: 2098-2104.
8. Riesterer O, Milas L, Ang KK,. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. [Review] [74 refs]. J Clin Oncol 2007; 25: 4075-4083.
9. Postema EJ, McEwan AJB, Riauka TA, et al. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2- nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging 2009; 36: 1565-1573.
10. Reischl G, Dorow DS, Cullinane C, et al. Imaging of tumor hypoxia with [124I] IAZA in comparison with [18F] FMISO and [18F] FAZA-first small animal PET results. J Pharm Pharm Sci 2007; 10: 203-211.
11. Busk M, Horsman MR, Jakobsen S, et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys 2008; 70: 1202-1212.
12. Reischl G, Ehrlichmann W, Bieg C, et al. Preparation of the hypoxia imaging PET tracer [18F] FAZA: reaction parameters and automation. Appl Radiat Isot 2005; 62: 897-901.
13. Binns DS, Pirzkall A, Yu W, et al. OSI3926g Study Team. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2011; 38: 642-650.
14. Koh WJ, Rasey J, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199-212.
15. McArthur GA, Amaravadi R, Ribas A, et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 2012; 30: 1628-1634.
16. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36: 417-428.
17. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253-260.
18. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33: 391-398.
19. Le Q-T, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006; 12: 1507-1514.
20. Graves EE, Vilalta M, Cecic IK, et al. Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res 2010; 16: 4843-4852.
21. Cherk MH, Foo SS, Poon AMT, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med 2006; 47: 1921-1926.
22. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J,. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008; 35: 2294-2303.
23. Nehmeh SA, Lee NY, Schroder H, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008; 70: 235-242.